REVIEW

It’s reticulated: the liver at the heart of atherosclerosis

Prabhakara R Nagareddy¹, Sunil K Noothi¹, Michelle C Flynn²,³ and Andrew J Murphy²,³

¹Department of Nutrition Sciences, University of Alabama, Birmingham, UK
²Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, Australia
³Department of Immunology, Monash University, Melbourne, Australia

Correspondence should be addressed to M C Flynn: michelle.flynn@baker.edu.au

Abstract

Platelets play a critical role in both the initiation and progression of atherosclerosis, and even more so in the ensuing atherothrombotic complications. Low-dose aspirin remains the mainstay of antiplatelet therapy in high-risk patients by reducing the risk of myocardial ischemia, stroke or death due to cardiovascular disease. However, antiplatelet therapies lose their efficacy in people with diabetes mellitus, increasing the risk of future atherothrombotic events. The molecular mechanisms that promote platelet hyperactivity remain unclear but could be due to glycation-induced conformational changes of platelet membranes resulting in impaired aspirin entry or less-efficient acetylation/compensatory increase in COX-2 expression in newborn platelets. Emerging evidence from our laboratory and elsewhere suggest that enhanced platelet turnover (thrombopoiesis), particularly the production of immature reticulated platelets from the bone marrow, could contribute to atherosclerotic complications. We have identified a major role for neutrophil-derived S100A8/A9, a damage-associated molecular pattern, in driving reticulated thrombopoiesis by directly interacting with its receptors on Kupffer cells in the liver. In this review, we discuss the role of hepatic inflammation in driving reticulated platelet production and suggest potential targets to control their production, improve efficacy of current antiplatelet therapies and reduce the risk of atherothrombotic complications.

Introduction

Coronary artery disease (CAD) has been the leading cause of death worldwide for the last few decades except in the very low-income group population (World Health Organisation 2017). Atherothrombosis and atherosclerosis are the pathologic basis for CAD and are widely appreciated to be multifactorial diseases with predominant factors of elevated lipid levels and chronic inflammation (Woollard & Geissmann 2010, Weber & Noels 2011). Emphasizing the role of lipids, statins have been the gold standard for treating CAD, and a large number of randomized controlled statin trials have confirmed their beneficial effects in various patient groups of CAD (Pedersen 2016). However, in the last three decades, evidence from experimental and clinical studies has also lent support to the inflammatory hypothesis in the pathogenesis of atherosclerotic disease in conjunction with or beyond elevated lipid levels (reviewed by Libby 2012). The recent results of the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) showed clinical evidence that controlling vascular inflammation...
independently of lipid lowering could lower the rates of recurrent cardiovascular events in a large Phase 3 trial (Ridker et al. 2017). Inflammatory signals likely cause plaque instability, which could result in plaque rupture, fissuring or erosion leading to a thrombotic response that causes myocardial infarction/ischemia (MI). However, strictly anti-inflammatory drugs have never been used alone to treat patients with CAD.

Elevated leukocyte count has been correlated with cardiovascular disease since the 1920s (Madjid et al. 2004). The myeloid compartment of the white blood cells (WBCs), namely, monocytes (Choi et al. 2017), neutrophils (Wheeler et al. 2004, Tan et al. 2015) and platelets (Huo et al. 2003), are the predominant players in driving this association and have all been causally implicated in influencing CAD initiation or progression and impairing the regression of atheromatous plaques. In this context, it is not surprising to note that aspirin, by virtue of its inhibition of platelet aggregation by blocking thromboxane A2 formation, has been used for several decades as the gold standard in secondary prevention of CAD (Antiplatelet Trialists’ Collaboration 1994).

Here, we review the common theme of myelopoiesis and more specifically, megakaryopoiesis, in driving the pathogenesis of CAD. We will examine the different pathways that promote the production of platelets, with an emphasis on reticulated platelets and the role of the liver in regulating megakaryopoiesis and thrombopoiesis.

### Cardiovascular risk factor contribution to myelopoiesis

As stated earlier, monocyte levels are associated with CAD. However, different metabolic risk factors for CAD seem to promote the production of monocytes through varying mechanisms. While these risk factors act through independent pathways, it is important to note that these risk factors typically cluster together in metabolic diseases such as diabetes and metabolic syndrome to promote an exacerbated myelopoietic phenotype. The mechanisms of each of these risk factors in relation to myeloid-driven CAD are summarized in Fig. 1 (modified from Murphy & Tall 2016) and detailed below.

**Figure 1**

Cardiovascular risk factors promote myelopoiesis and accelerate atherosclerosis. (A) Dyslipidemia in the form of increased LDL and decreased HDL directly promotes HSPC differentiation via impaired cholesterol efflux in these cells. (B) Obesity indirectly promotes myelopoiesis by stimulating IL-1β production from ATM in VAT. (C) Hyperglycemia induces an upregulation in S100A8/A9 that travels to BM to stimulate myelopoiesis. ATM, adipose tissue macrophages; BM, bone marrow; HSPC, hematopoietic stem and progenitor cell; VAT, visceral adipose tissue.
Dyslipidemia

Dyslipidemia refers to abnormal amounts of lipids in the blood and is a central component of both diabetes and metabolic syndrome, typically presenting as hyperlipidemia with an increase in triglycerides and LDL cholesterol with a reduction in HDL cholesterol. In the context of dyslipidemia, lipid metabolism and cholesterol efflux are important regulators of myeloid cell production. The importance of lipids in regulating bone marrow (BM) hematopoietic stem and progenitor cell (HSPC) proliferation was originally discovered through the use of genetically deficient models of key cholesterol efflux genes, including ABCA1 and ABCG1, (ATP-binding cassette (ABC) transporters, belonging to a family of highly conserved cellular transmembrane proteins) as well as their cell-intrinsic ligand apolipoprotein E. Deletion of these genes resulted in cholesterol accumulation, enhanced proliferation and over production of monocytes and neutrophils (Yvan-Charvet et al. 2010, Murphy et al. 2011) (Fig. 1A). Importantly, this phenotype could be reversed by increasing HDL levels to promote cholesterol efflux through either genetic or pharmacological approaches. It was also revealed that concurrently increasing LDL levels and reducing HDL levels using a genetic approach further influenced the proliferation of HSPCs resulting in enhanced monocytes and accelerated atherosclerosis (Tolani et al. 2013). Thus, regulating HSPC cholesterol content is important in maintaining normal hematopoiesis to prevent the overproduction of myeloid cells that exacerbate atherosclerosis in the presence of dyslipidemia.

Obesity

Obesity is known as a low-grade inflammatory disorder with a heavy macrophage burden of the adipose tissue (Weisberg et al. 2003). This discovery brought forward the hypothesis that signals emanating from this organ could have detrimental effects on the health of other organs around the body. This was recently demonstrated in the liver, where obese adipose tissue drove hepatic neutrophil recruitment (Bijnen et al. 2017). Similarly, seeding of monocytes in the visceral adipose tissue (VAT) was shown to involve a regulatory feed-forward loop where inflamed VAT can signal to BM hematopoietic progenitor cells to proliferate, expand and increase the production of myeloid cells (Nagareddy et al. 2014) (Fig. 1B). Specifically, we discovered that upregulation of S100A8/A9 in the VAT, signal adipose tissue macrophages (ATMs) to induce the expression of Pro-IL-1β and the Nlrp3 inflammasome. Activation of the Nlrp3 inflammasome by a second signal (yet to be clearly defined) results in the processing of Pro-IL-1β to form mature IL-1β, which then travels to the BM to induce the proliferation of hematopoietic progenitor cells (common myeloid progenitors (CMPs) and granulocyte macrophage progenitors (GMPs)) resulting in monocytes and neutrophilia (Nagareddy et al. 2014). The excess number of monocytes in the circulation gives rise to more ATMs which in turn trigger further adipose inflammation completing the loop and also promote insulin resistance. Given the positive outcome, albeit small, in reducing cardiovascular events in the CANTOS trial, alongside the remaining controversy over the explicit role of IL-1β in the general pathogenesis of atherosclerosis (Duewell et al. 2010, Menu et al. 2011, Ridker et al. 2017), it will be of specific interest to determine whether those of greatest benefit with IL-1β-targeted therapies are those obese individuals, particularly those with a recent cardiovascular event. Additionally, but beyond the scope of this review, another sub-group of patients that could benefit from IL-1β-targeted therapies are those with clonal hematopoiesis of indeterminate potential, particularly those with TET-2 mutations (Fuster et al. 2017, Jaiswal et al. 2017) or patients with IL-1β associated autoimmune disorders such as rheumatoid arthritis that is linked to accelerated CVD (Dragoljevic et al. 2018).

Hyperglycemia

It is well known that people with diabetes have elevated WBC counts (Schmidt et al. 1999, Ford 2002, Vuckovic et al. 2007, Woo et al. 2011). Modeling this in mice, we discovered that hyperglycemia promotes myelopoiesis by increasing the release of S100A8/A9 from neutrophils, which then interacts with the glucose-inducible receptor for advanced glycation end-products (RAGE) on CMPs, resulting in the production of inflammatory Ly6-C<sup>+</sup> monocytes. The importance of this finding was that the increased production of Ly6-C<sup>+</sup> monocytes contribute to persistent entry into the atherosclerotic lesion, impairing lesion regression as previously documented (even when cholesterol levels were effectively lowered) (Fig. 1C) (Nagareddy et al. 2013). Impaired lesion regression has also been observed in people with diabetes, even though LDL levels were lowered equally by statin treatment in comparison to people without diabetes (Hiro et al. 2010) and modeled
in mice (Parathath et al. 2011). In the pre-clinical models, we found that this myelopoietic defect could be reversed by administration of an sodium-glucose cotransporter 2 inhibitor (SGLT2i), and given the recent success of this class of drugs in reducing cardiovascular events in people with diabetes (Nagareddy et al. 2013), it will be important to explore if the reduction is due to a dampening in the production of myeloid cells. Interestingly, dysregulated cholesterol metabolism has also been alluded to in the setting of diabetes (Passarelli et al. 2005, Mauldin et al. 2008), and silencing miR33, a negative regulator of ABCA1, can suppress myeloid cells in the setting of diabetes (Distel et al. 2014). Therefore, it would also be interesting to determine if elevating HDL could reverse enhanced myelopoiesis in diabetes, with benefits that extend to the vasculature.

Platelets and atherosclerosis

Apart from the intrinsic thrombotic tendency of platelets, platelet biogenesis plays an important role in atherogenesis due to two main reasons. First, more activated platelets are found in the circulation of patients with CAD (Fitzgerald et al. 1986, Schapiro et al. 1990), hypercholesterolemia (Brojersen et al. 1998) and diabetes (Grove et al. 2011), which are prone to bind leukocytes, preferentially monocytes, to form platelet–leukocyte aggregates (Rinder et al. 1992, Furman et al. 1998) required for thrombus evolution. The enhanced platelet production also causes an increase in immature or reticulated platelets, which is invariably linked to accelerated atherogenesis (Murphy et al. 2013). Secondly, activated platelets can produce chemokines to exacerbate atherogenesis. For example, platelet CD40L (Henn et al. 1998) and IL-1β (Hawrylowicz et al. 1991) can activate endothelial cells or platelets can deposit chemokines including platelet factor-4 (PF4/ CXCL4) and RANTES (CCL5), which can trigger monocyte arrest on inflamed endothelium (von Hundelshausen et al. 2001). It should be noted that antiplatelet therapy can reduce CVD risk in non-diabetic subjects (Antiplatelet Trialists’ Collaboration 1994); however, such therapies are less effective in the context of diabetes, potentially due to an increase in reticulated platelets that are somewhat resistant to standard antiplatelet therapies (Guthikonda et al. 2007), possibly due to their ability to re-synthesize cyclooxygenase (COX)-1 and COX-2. This is because reticulated platelets, unlike mature platelets carry residual mRNA that may help replenish COX enzymes (Angénieux et al. 2016).

Reticulated platelets and aspirin resistance

Antiplatelet drugs decrease platelet aggregation and prevent thrombus formation, even in the arterial circulation where anticoagulants are generally ineffective. The major classes of antiplatelet drugs are irreversible COX inhibitors such as aspirin and ADP receptor inhibitors (e.g. clopidogrel). However, in the last couple of decades, inter-individual variability of platelet inhibition by antiplatelet therapies of aspirin and clopidogrel has been observed. As early as 2003, Gurbel et al. showed that the platelet inhibitory response from clopidogrel varied enormously and that patients undergoing elective coronary stenting were least protected when their ex vivo platelet reactivity was high to begin with (Gurbel et al. 2003, Vlachojannis et al. 2011). Similarly, inter-individual variability of platelet reactivity with aspirin has been termed aspirin resistance. Aspirin inhibits platelet activation by irreversible acetylation of platelet COX-1, thereby preventing the formation of thromboxane A2. Even though the half-life of aspirin is minutes, COX-1 modification by aspirin is sufficient for platelet inhibition for up to 24 h as platelets are anucleate and, due to mRNA degradation, mature platelets lack sufficient mRNA required to replenish COX-1 protein (Patrono et al. 2005, Angénieux et al. 2016). It has been estimated that with low-dose aspirin, COX-1 activity is restored at a rate of 10% per day reflecting the 10-day lifespan of platelets, where 10% of the platelets are newly formed and not exposed to aspirin (Eikelboom & Warkentin 2014). Even though part of the inter-individual variability of platelet inhibition can be attributed to inherent variations in ex vivo measurements and polymorphisms of cytochrome P450 2C19 (Shuldiner et al. 2009), it is now well-accepted that new platelet generation plays a significant mechanistic role. Like increased reticulocyte (immature erythrocyte) count use as a marker for enhanced erythropoiesis, immature platelet counts (IPCs) and reticulated platelet fractions (RPFs) have emerged as a marker for increased thrombopoiesis. Immature or reticulated platelets are larger, metabolically more active and have a higher thrombotic potential than mature platelets (Brown & Martin 1994). Although the terms ‘reticulated platelets’ and ‘immature platelets’ are used interchangeably, reticulated platelets are detected by flow cytometry with thiazole orange staining of the high RNA content in a reticulated pattern (hence the name ‘reticulated platelets’) (Kienast & Schnitz 1990), while ‘immature’ platelets are detected on automated cell counters with an add-on module allowing platelets to be stained with a polyamine/oxazine combination
Platelet production and atherosclerosis

Reticulated platelet count has been strongly associated with aspirin resistance, especially with short-lived antiplatelet therapies as they can re-synthesize COX-1/2 (Guthikonda et al. 2007, 2008, Armstrong et al. 2017). However, IPC has emerged as the strongest independent platelet count-derived predictor of antiplatelet response (Stratz et al. 2016). In a prospective study of 93 subjects with a median follow-up of 31 months, IPC has also been associated with major adverse cardiovascular events (MACEs), defined as a composite of death, MI, unplanned revascularization or recurrent angina (Ibrahim et al. 2014). RPF as an index of platelet turnover has also been shown to be an independent predictor of MACE (Freyhhofer et al. 2017). Thrombi generated in a perfusion chamber with whole blood from normal donors under shear conditions equivalent to a significant coronary artery stenosis, revealed that younger ‘reticulated’ platelets had greater propensity for thrombus participation compared to older and mature platelets (McBane et al. 2014).

Diabetes is associated with a higher number of clopidogrel non-responders and increased platelet reactivity on combined aspirin and clopidogrel treatment (Angiolillo et al. 2005). Moreover, patients with DM but without any history of coronary event such as MI carry the same level of risk as a non-diabetic MI patient for subsequent acute coronary events (Schramm et al. 2008). Significantly higher mean platelet volume (MPV), which is also a risk factor for MACE (Mayer et al. 2014), was seen in diabetic patients compared to non-diabetic controls, suggesting a platelet dependent role in the macrovascular complications of diabetes (Hekimsoy et al. 2004). Not surprisingly, diabetic patients with CAD have significantly higher MPV values compared to control subjects (Tavil et al. 2010). Hence, diabetic patients exhibit a prothrombotic milieu with reticulated and hyperreactive platelets, and a consistently impaired response to antiplatelet therapy (reviewed by Neergaard-Petersen et al. 2016).

Megakaryopoiesis and its regulation by the liver

Platelets are produced through the myelopoietic pathway in the BM, specifically through the differentiation of hematopoietic stem cells through to megakaryocyte-erythroid progenitors (MEPs), then megakaryocyte progenitors (MkPs) and megakaryocytes before undergoing thrombopoiesis to form platelets. The primary cytokine regulator of megakaryopoiesis is thrombopoietin (TPO), which is constitutively produced by hepatocytes in the liver and to a lesser degree by proximal tubule cells in the kidney (Sungaran et al. 1997, Qian et al. 1998). TPO acts via its receptor, the cellular homologue of the myeloproliferative leukemia virus oncogene (c-MPL) on platelets and BM progenitor cells (de Sauvage et al. 1994, Kuter et al. 1994). Clearance of senescent desialylated platelets in the liver via the Ashwell–Morell receptor (AMR) induces STAT-3-mediated production of TPO in hepatocytes (Hoffmeister et al. 2014). When circulating platelets are low, plasma TPO levels increase and promote thrombopoiesis by binding to MEPs, MkPs and megakaryocytes. Mice lacking TPO or MPL are severely thrombocytopenic and deficient in megakaryocytes and their progenitor cells (Gurney et al. 1994, Kaushansky 1995), a phenotype consistent with a role for TPO in maintaining appropriate megakaryocyte numbers in vivo. Platelet mass contains the highest concentration of c-MPL receptor and MPL-receptor-mediated internalization and degradation through ubiquitination regulates systemic TPO levels (Saur et al. 2010). After the platelets are released into the circulation, they act as a sink, binding to c-MPL and degrading TPO, which decreases platelet production (Saur et al. 2010). This feedback system effectively regulates TPO-driven platelet production in normal physiological conditions. The reciprocal relationship between platelet number (aka ‘MPL mass’) and circulating TPO levels may be an effective feedback loop during normal, but not in inflammatory conditions. For example, cytokines such as IL-6 and IL-1α can stimulate thrombopoiesis independent of platelet number or “MPL mass”, indicating that the number of platelets by themselves is not the sole determinant of circulating TPO levels and thus of thrombopoiesis (Gurney et al. 1994, Broudy et al. 1995, Saur et al. 2010). During acute inflammation, TPO levels rise and a positive correlation is seen between the concentrations of circulating IL-6 and TPO (Hsu et al. 1999, Ishiguro et al. 2002). In fact, IL-6 has been shown to act directly on hepatocytes via the IL-6R to induce TPO expression, which is mediated by gp130-JAK1 activation of STAT3 independent to classical signaling via the hepatic AMR (Kaser et al. 2001, Hoffmeister et al. 2014). Systemic TPO levels have been shown to be increased in diabetes and are associated with glycemia, insulinemia and adiposity (Maury et al. 2010). Likewise, IL-6 is elevated in diabetes and metabolic syndrome and...
plays an important role in glucose metabolism, notably reducing hepatocyte insulin sensitivity (Pickup et al. 1997, Kristiansen & Mandrup-Poulsen 2005). In the liver, IL-6 expression by Kupffer cells is increased in diabetes (Kraakman et al. 2017), and this cytokine may play an important role in diabetes-induced thrombopoiesis. In contrast to the increased thrombopoiesis observed during inflammation, impaired liver function in patients with liver cirrhosis (LC) (Afdhal et al. 2008) and in hepatitis B virus (HBV)-related liver disease (Wang et al. 2014a) is associated with 76% incidence of thrombocytopenia. The prevalence of cirrhosis as an etiology of thrombocytopenia of unknown origin in patients undergoing BM biopsies is as high as 35% (Sheikh et al. 2012). LC patients typically present with decreased plasma TPO, decreased platelet production as well as accelerated platelet destruction (Pradella et al. 2011). Further, confirming the role of liver in thrombopoiesis, orthotopic liver transplantation in patients with LC induces platelet recovery through an increase in systemic TPO levels (Peck-Radosavljevic et al. 2000).

Cardiovascular risk factor contribution to megakaryopoiesis

Dyslipidemia

As is the case in diabetes, patients identified as hyperlipidemic also exhibit increased platelet activation (Podrez et al. 2007, Vergeer et al. 2011), higher platelet counts and increased MPV (Vergeer et al. 2011) indicating that dyslipidemia may play a direct role in platelet production and/or function and contribute to diabetes-associated thrombocytosis. For example, deficiency of ATP-binding cassette transporter B6 (ABCB6) and cholesterol transporter ABCG4, which promote cholesterol efflux to HDL in MkPs, can both lead to expansion and proliferation of MkPs (Murphy et al. 2013, 2014) (Fig. 2A). ABCB6 is restricted to MEPs (Murphy et al. 2014) while ABCG4 has been shown to be highly expressed in BM MkPs (Murphy et al. 2013). Enhanced megakaryopoiesis in the absence of ABCB6 was accompanied by increased platelet counts, MPV and platelet activity together with
increased platelet–leukocyte aggregates and accelerated atherosclerosis (Murphy et al. 2014). In the absence of ABCG4, MkPs showed defective cholesterol efflux to HDL, increased cell surface expression of the TPO receptor, c-MPL, followed by enhanced proliferation and megakaryopoiesis (Nagareddy et al. 2013). Mechanistically, disruption of negative feedback regulation of c-MPL signaling by the E3 ligase c-CBL and the cholesterol-sensing LYN kinase was implicated. Interestingly, infusions of reconstituted HDL could reverse this phenotype in an ABCG4-dependent fashion. It is pertinent to note that people with myeloproliferative neoplasms like essential thrombocytosis and polycythemia vera, often die of atherothrombotic disease (Murphy & Tall 2016). However, the mechanism of enhanced thrombocytosis in these patients is due to cell-intrinsic mutations in MkPs and other BM progenitors resulting in uncontrolled proliferation (Maugeri et al. 2011), which is different from megakaryopoiesis associated with CAD risk factors where the culprits are usually extrinsic. In the case of altered lipid levels, this extrinsic mediator is the abnormal cholesterol efflux in hematopoietic progenitors. In addition, while cholesterol handling of stem and progenitor cells in the BM plays an important role in regulating myelopoiesis and alterations in MkP cholesterol efflux leads to enhanced megakaryopoiesis, it is also possible that more global effects of dyslipidemia, particularly in the liver, may contribute to lipid-induced megakaryopoiesis.

**Hyperglycemia**

The residual risk of CVD in diabetes despite lipid lowering, as described earlier, implies that there are major gaps in our understanding of the underlying mechanisms responsible for increased CVD in diabetes. In our recent study, we unraveled a novel link between hyperglycemia and enhanced platelet production and reactivity (Kraakman et al. 2017). We found that diabetic mice had significantly higher production of reticulated platelets through overall expansion of BM progenitor populations, specifically, CMPs, MEPs and MkPs (Fig. 2B). This appeared to be driven by TPO originating from the liver, as IL-6-driven liver inflammation was evident. Transplantation of IL-6-knockout BM followed by injection of streptozotocin (STZ) led to normalized levels of reticulated platelets and BM MkPs without any decrease in liver Kupffer cell numbers. This implied that IL-6 downstream of Kupffer cells is the key mediator of diabetes-associated thrombocytosis through induction of TPO (Kraakman et al. 2017). In a cohort of diabetic patients, increased plasma levels of TPO were also observed, similar to our pre-clinical model (Grove et al. 2011, Kraakman et al. 2017). Through a series of bone marrow transplant (BMT) studies using BM from different genetic deficient models, we found that neutrophil-derived S100A8/A9, binding to the RAGE on the Kupffer cells from diabetic mice caused increases in Kupffer cell abundance and IL-6 expression, consistent with the increased inflammatory tone of the liver. Furthermore, S100a9−/− mice or hematopoietic deletion of S100A9 through BMTs also protected mice from diabetes-induced thrombocytosis confirming that the source of the ligands was hematopoietic cells. Independent of hyperglycemia, S100A8/A9 is also known to contribute to the biological response by promoting leukocyte recruitment in vascular injury and regulate thrombosis (Croce et al. 2009, Wang et al. 2014b).

Neutrophils are the predominant source of the serum S100A8/A9 (Nagareddy et al. 2013) and neutrophil depletion using an anti-Ly6-G antibody in diabetic mice caused significant lowering of circulating platelets and BM MEPs. Increased serum S100A8/A9 is a biomarker for chronic inflammatory disorders and localizes to sites of infection or sterile injury (Pruenster et al. 2016). Does this imply that neutrophils are sensors of hyperglycemia? Indeed, neutrophil depletion studies decrease the levels of S100A8/A9. It is interesting to note that leukocytes have differential glycolytic and oxidative metabolic profiles where lymphocytes primarily rely on oxidative phosphorylation to metabolize glucose, while neutrophils are almost entirely glycolytic with platelets and monocytes being relatively intermediate (Kramer et al. 2014). S100A8/A9 levels were increased in a cohort of individuals with type 1 diabetes (T1D) with complications (Nagareddy et al. 2013) and similar to results in mice, type 2 diabetes mellitus (T2DM) patients had a significant increase in the abundance of reticulated platelets that correlates with glycated hemoglobin as well as increased plasma S100A8/A9 levels. Our studies have identified two potential therapeutic strategies: (1) mice treated with SGLT2i, dapagliflozin, lowered blood glucose concomitantly with reduced number of reticulated platelets; (2) STZ-treated mice ameliorated their diabetes-induced atero-progression with S100A9 inhibitor ABR-215757. Not surprisingly, in the EMPA-REG OUTCOME trial a SGLT2i, empagliflozin, reduced cardiovascular morbidity and mortality in patients with T2DM and established cardiovascular disease (Wanner et al. 2018). It would be interesting to see the effect of S100A8/A9 targeting small-molecule inhibitor ABR-215757 (Paquinimid) in diabetic patients, which has already
been shown to have fewer side effects and encouraging pharmacokinetics in a dose-ranging study with cohorts of systemic lupus erythematous (SLE) patients (Bengtsson et al. 2012).

**Conclusions**

Diabetes is associated with enhanced atherosclerosis and atherothrombosis, which is resistant to antiplatelet therapies. Liver inflammation in diabetes as well as impaired cholesterol efflux in the platelet-lineage progenitor cells promotes megakaryopoiesis and leads to reticulated thrombopoiesis, generating new platelets uninhibited by antiplatelet drugs, increasing platelet activity and accelerating atherosclerosis. S100A8/A9 from neutrophils induced by hyperglycemia promotes this liver inflammation, resulting in the IL-6-mediated production of the megakaryopoiesis-inducing factor, TPO, in the liver. S100A8/A9 also both directly and indirectly promotes the production of monocytes and neutrophils through enhanced myelopoiesis in the context of hyperglycemia and obesity. Moreover, dyslipidemia and impaired cholesterol efflux in the stem and progenitor cells upstream of monocytes and neutrophils also contributes to enhanced myelopoiesis and accelerates atherosclerosis. Given the cumulative effects of these risk factors underlying CVD in promoting thrombocytopoiesis and in generating reticulated platelets resistant to antiplatelet drugs such as aspirin, it is unsurprising that current therapies for thrombocytopoiesis often fail to achieve effective platelet inhibition. This is particularly evident in patients with diabetes, resulting in persistent high platelet reactivity, which is associated with an increased risk of cardiovascular events. Targeting platelet production along with mature platelet reactivity may provide a more effective and reliable approach to reducing thrombocytopoiesis associated with metabolic disease. Moreover, while the potential additive or synergistic effects of inhibiting S100A8/A9 alongside lipid lowering to inhibit thrombocytopoiesis is yet to be explored, these data suggest that combined targeting of these pathways could be beneficial in lowering platelet activity as well as monocyte and neutrophil levels in patients with metabolic diseases and have the overall potential to reduce CVD in these ‘at-risk’ patients.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as influencing the objectivity of this review.

**References**


Platelet production and atherosclerosis

Eikelboom JW & Warkentin TE 2014 Immature platelet count: part of the Thrombosis and Haemostasis 5 490–496. (https://doi.org/10.1111/j.1538-7836.2007.02387.x)


Kristensen OP & Mandrup-Poulsen T 2005 Interleukin-6 and diabetes: the good, the bad, or the indifferent? *Diabetes* **54** S114–S124. (https://doi.org/10.2337/diabetes.54.supp2_S114)


Received in final form 3 April 2018
Accepted 2 May 2018
Accepted Preprint published online 2 May 2018